The promising monoclonal agent, etaracizumab, previously identified as MEDI523 or LM609, represents a significant advance in complement regulator progress. It's specifically designed to block the impact of factor B, a pivotal protein in the lectin pathway of the inflammatory system. Studies are c… Read More

Datopotamab Deruxtecan, often abbreviated as DATO, represents a significant advancement regarding targeted cancer treatment. This innovative antibody-drug conjugate joins an monoclonal antibody specifically directed at HER-2 expressing cells with the potent chemotherapeutic payload, deruxtecan. T… Read More